Over the past two decades, the number of FDA-approved treatments for multiple myeloma (MM) has increased substantially. This growth in available agents has made frontline treatment decisions more complex and introduced variability in how new therapies are adopted in routine clinical practice. The changing therapeutic landscape underpins the need to examine real-world treatment patterns and outcomes outside the controlled environment of randomized clinical trials.
Randomized clinical trials have guided MM treatment strategies and demonstrated survival benefits with novel agents. However, trials frequently exclude older adults, patients with substantial medical comorbidity, and those who are socioeconomically disadvantaged. Consequently, trial populations may not reflect the demographics and complexity of patients seen in everyday practice. The national Veterans Affairs (VA) health system represents a unique, large-scale, equal-access setting in which cost is less often a limiting factor. Studying treatment patterns and outcomes in the VA therefore offers insight into how therapies are used and perform across a diverse, real-world population.
The investigators performed a retrospective evaluation of 20,135 patients with newly diagnosed multiple myeloma treated within the VA between 2000 and 2024. The analysis spanned multiple diagnosis eras corresponding to changes in the therapeutic armamentarium. The cohort size and extended time frame allowed assessment of longitudinal trends in frontline regimen selection and survival outcomes in an integrated health-care system.
Analyses focused on overall survival by frontline treatment regimen and by diagnosis era, and examined associations between sociodemographic factors and outcomes. Socioeconomic status was approximated using the area deprivation index (ADI). By combining regimen-level, era-level, and sociodemographic analyses, the study aimed to disentangle temporal improvements in outcomes from persistent disparities across patient groups.
A principal finding was that lower socioeconomic status, as estimated by the area deprivation index, was independently associated with increased mortality even within the VA’s equal-access environment. This observation indicates that equitable access to care alone does not eliminate outcome disparities tied to structural and social determinants of health. The study highlights that nonfinancial barriers and the broader context of socioeconomic deprivation can influence survival in MM.
Overall survival improved across successive treatment eras, consistent with the introduction and adoption of novel therapies. The study notes, however, that follow-up for patients diagnosed in the most recent era is limited, so long-term survival outcomes for the newest cohorts remain incompletely characterized. The variable uptake of new agents in clinical practice and limited follow-up for recent diagnoses both constrain definitive conclusions about long-term benefit across the entire study period.
The cohort emphasizes that trial-based evidence does not always generalize to the broader MM population, particularly to older, medically complex, or socioeconomically disadvantaged patients frequently underrepresented in randomized studies. Real-world analyses such as this one complement trial data by documenting how frontline treatments are used in practice and by revealing outcome patterns across populations that trials may not capture.
In this large retrospective VA cohort of 20,135 patients diagnosed with multiple myeloma from 2000 to 2024, outcomes have improved over time but disparities by socioeconomic status persist. The independent association between higher ADI and increased mortality despite equal-access care points to the need for targeted strategies that address social and structural barriers to optimal MM care. The authors conclude that implementing interventions focused on these determinants is essential to achieve more equitable survival gains across patient populations. The source did not report specific intervention trials or detailed programmatic solutions, and such details were not provided in the abstract.